JP2010510242A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510242A5 JP2010510242A5 JP2009537394A JP2009537394A JP2010510242A5 JP 2010510242 A5 JP2010510242 A5 JP 2010510242A5 JP 2009537394 A JP2009537394 A JP 2009537394A JP 2009537394 A JP2009537394 A JP 2009537394A JP 2010510242 A5 JP2010510242 A5 JP 2010510242A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- phenyl
- alkyl
- hydrogen
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 150000003973 alkyl amines Chemical class 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- -1 carboalkyl Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000003584 mesangial cell Anatomy 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 C*C(C=CC=C(C)*(C)=C)=CN Chemical compound C*C(C=CC=C(C)*(C)=C)=CN 0.000 description 16
- YAIVAQAWIKGLOS-UHFFFAOYSA-N CC(C)C1=COCC(C)(C)N1 Chemical compound CC(C)C1=COCC(C)(C)N1 YAIVAQAWIKGLOS-UHFFFAOYSA-N 0.000 description 1
- FRGXNJWEDDQLFH-UHFFFAOYSA-N CC(C)c1ccncc1 Chemical compound CC(C)c1ccncc1 FRGXNJWEDDQLFH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86608006P | 2006-11-16 | 2006-11-16 | |
| PCT/US2007/084999 WO2008061236A2 (en) | 2006-11-16 | 2007-11-16 | Sulfoximines as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510242A JP2010510242A (ja) | 2010-04-02 |
| JP2010510242A5 true JP2010510242A5 (enExample) | 2010-11-18 |
Family
ID=39284047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537394A Pending JP2010510242A (ja) | 2006-11-16 | 2007-11-16 | キナーゼ阻害剤としてのスルホキシミン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7915443B2 (enExample) |
| EP (1) | EP2099757B1 (enExample) |
| JP (1) | JP2010510242A (enExample) |
| AU (1) | AU2007319151B2 (enExample) |
| BR (1) | BRPI0718895A2 (enExample) |
| CA (1) | CA2669704A1 (enExample) |
| WO (1) | WO2008061236A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456476B2 (en) | 2003-06-27 | 2008-11-25 | Intel Corporation | Nonplanar semiconductor device with partially or fully wrapped around gate electrode and methods of fabrication |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7042009B2 (en) | 2004-06-30 | 2006-05-09 | Intel Corporation | High mobility tri-gate devices and methods of fabrication |
| US20060086977A1 (en) | 2004-10-25 | 2006-04-27 | Uday Shah | Nonplanar device with thinned lower body portion and method of fabrication |
| US7518196B2 (en) | 2005-02-23 | 2009-04-14 | Intel Corporation | Field effect transistor with narrow bandgap source and drain regions and method of fabrication |
| US7858481B2 (en) | 2005-06-15 | 2010-12-28 | Intel Corporation | Method for fabricating transistor with thinned channel |
| US7547637B2 (en) | 2005-06-21 | 2009-06-16 | Intel Corporation | Methods for patterning a semiconductor film |
| US7279375B2 (en) * | 2005-06-30 | 2007-10-09 | Intel Corporation | Block contact architectures for nanoscale channel transistors |
| US20070090416A1 (en) | 2005-09-28 | 2007-04-26 | Doyle Brian S | CMOS devices with a single work function gate electrode and method of fabrication |
| US7485503B2 (en) | 2005-11-30 | 2009-02-03 | Intel Corporation | Dielectric interface for group III-V semiconductor device |
| WO2007087419A2 (en) | 2006-01-24 | 2007-08-02 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl) -1, 3-dihydro-indol-2-one derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| US8143646B2 (en) | 2006-08-02 | 2012-03-27 | Intel Corporation | Stacking fault and twin blocking barrier for integrating III-V on Si |
| US8558002B2 (en) * | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
| US8642067B2 (en) * | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US8362566B2 (en) | 2008-06-23 | 2013-01-29 | Intel Corporation | Stress in trigate devices using complimentary gate fill materials |
| AR076332A1 (es) | 2009-04-21 | 2011-06-01 | Boehringer Ingelheim Int | Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones. |
| US20100278897A1 (en) * | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Intraocular bioactive agent delivery system with molecular partitioning system |
| CN105916850B (zh) * | 2013-12-12 | 2020-03-20 | 阿勒根公司 | 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物 |
| BR112016013539A2 (pt) | 2013-12-12 | 2020-10-27 | Allergan, Inc. | derivados de nicotinamida substituídos como inibidores de quinase e seu uso |
| CN111662227B (zh) * | 2019-03-06 | 2022-07-05 | 中国科学院上海药物研究所 | 邻氨基吡啶炔类化合物及其制备方法和用途 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2383874A (en) * | 1941-04-24 | 1945-08-28 | Swiss Firm Of J R Geigy A G | p-aminobenzenesulphonamides and a process for their manufacture |
| GB602558A (en) * | 1945-10-24 | 1948-05-28 | Geigy Ag J R | Manufacture of aromatic acyl-sulphonamides |
| DE821977C (de) * | 1949-10-02 | 1951-11-22 | Basf Ag | Verfahren zur Herstellung von Azofarbstoffen |
| EP0075377A3 (en) * | 1979-07-18 | 1983-08-31 | Imperial Chemical Industries Plc | Diphenyl ether compounds, their use as herbicides, and herbicidal compositions containing them |
| ZA804076B (en) * | 1979-07-18 | 1981-06-24 | Ici Ltd | Herbicides |
| GB2061914A (en) * | 1979-11-01 | 1981-05-20 | American Cyanamid Co | Substituted anilines and their use as anti-atherosclerotic agents |
| JPS5998056A (ja) * | 1982-11-04 | 1984-06-06 | エフ・ホフマン−ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト | 除草活性を有する安息香酸誘導体 |
| EP0109575A3 (de) | 1982-11-04 | 1984-09-05 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Benzoesäurederivate, Verfahren und Mittel zu deren Herstellung |
| JPS5890555A (ja) * | 1982-11-22 | 1983-05-30 | Ishihara Sangyo Kaisha Ltd | ベンズアミド誘導体及びそれらを含有する除草剤 |
| JPS6216465A (ja) * | 1985-03-14 | 1987-01-24 | Nissan Chem Ind Ltd | ベンズアミド誘導体、その製法および土壌病害防除剤 |
| US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| WO1988006886A1 (en) * | 1987-03-18 | 1988-09-22 | American Home Products Corporation | Sulfonylcarboxamides |
| US4826990A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| CA2078214C (en) | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2068355A1 (en) * | 1991-05-14 | 1992-11-15 | Mark S. Chambers | Benzodiazephine derivatives, compositions containing them and their use in therapy |
| WO1992021660A1 (en) | 1991-05-29 | 1992-12-10 | Pfizer, Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| JP2600644B2 (ja) * | 1991-08-16 | 1997-04-16 | 藤沢薬品工業株式会社 | チアゾリルベンゾフラン誘導体 |
| JPH05294930A (ja) * | 1992-04-21 | 1993-11-09 | Yoshitomi Pharmaceut Ind Ltd | スチリル化合物 |
| SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| EP0666868B2 (en) | 1992-10-28 | 2006-06-14 | Genentech, Inc. | Use of anti-VEGF antibodies for the treatment of cancer |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| DE4410453A1 (de) * | 1994-03-25 | 1995-09-28 | Hoechst Ag | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| KR970707098A (ko) * | 1994-10-27 | 1997-12-01 | 후지야마 아키라 | 브라디키닌 길항제로서 피리도피리미돈, 퀴놀린 및 융합된 N-헤테로사이클(Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists) |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| HUP9900625A3 (en) * | 1995-12-28 | 2003-04-28 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives, pharmaceutical compositions containing them and process for preparing the compounds |
| AU7552198A (en) * | 1997-06-11 | 1998-12-30 | Sankyo Company Limited | Benzylamine derivatives |
| CN1325385A (zh) | 1998-11-09 | 2001-12-05 | 詹姆斯·布莱克基金有限公司 | 胃泌素和缩胆囊素受体配体 |
| KR20020081469A (ko) * | 2000-03-22 | 2002-10-26 | 바이엘 크롭사이언스 게엠베하 | 헤테로사이클릭 아실설피미드, 이의 제조방법, 이를포함하는 제제 및 살충제로서의 용도 |
| DE10021246A1 (de) * | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| US20020054093A1 (en) | 2000-10-04 | 2002-05-09 | Gonzalez Emmanuel C. | Ergonomic graphic interface for webpages, internet browsers and computers |
| JP2002205464A (ja) * | 2000-11-10 | 2002-07-23 | Oji Paper Co Ltd | 感熱記録体 |
| ES2257461T3 (es) | 2000-12-21 | 2006-08-01 | Bristol-Myers Squibb Company | Inhibidores de tiazolilo de tirosina quinasas de la familia tec. |
| AU2003257170B2 (en) * | 2002-08-09 | 2008-12-11 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2005108370A1 (ja) * | 2004-04-16 | 2005-11-17 | Ajinomoto Co., Inc. | ベンゼン化合物 |
| DE102004031323A1 (de) * | 2004-06-29 | 2006-01-19 | Bayer Cropscience Ag | Substituierte Pyridazincarboxamide und Derivate hiervon |
| WO2006013449A1 (en) | 2004-07-30 | 2006-02-09 | Adriaan Francois Roberts | A swimming pool installation and accessory |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1863805A1 (en) | 2005-02-01 | 2007-12-12 | AstraZeneca AB | Pyrimidine compounds having tie2 (tek) inhibitory activity |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| AU2006227778A1 (en) * | 2005-03-16 | 2006-09-28 | Janssen Pharmaceutica N.V. | Novel thiophene sulfoximines for treating complement-mediated diseases and conditions |
| EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
| JP2008534565A (ja) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Ｔｉｅ２阻害活性のあるアミノピリミジン誘導体 |
| JP5200939B2 (ja) | 2005-12-23 | 2013-06-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 二環式ヘテロアリール化合物 |
| DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| TW200930369A (en) * | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
-
2007
- 2007-11-16 CA CA002669704A patent/CA2669704A1/en not_active Abandoned
- 2007-11-16 JP JP2009537394A patent/JP2010510242A/ja active Pending
- 2007-11-16 WO PCT/US2007/084999 patent/WO2008061236A2/en not_active Ceased
- 2007-11-16 BR BRPI0718895-1A patent/BRPI0718895A2/pt not_active IP Right Cessation
- 2007-11-16 EP EP07864544.7A patent/EP2099757B1/en not_active Not-in-force
- 2007-11-16 AU AU2007319151A patent/AU2007319151B2/en not_active Ceased
- 2007-11-16 US US11/941,753 patent/US7915443B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510242A5 (enExample) | ||
| JP2020033357A5 (enExample) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2317291C2 (ru) | Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1), фармацевтическая композиция, способы получения (варианты) и применение | |
| JP2006525298A5 (enExample) | ||
| JP2011502958A5 (enExample) | ||
| JP2009530281A5 (enExample) | ||
| JP2020515575A5 (enExample) | ||
| JP2010530438A5 (enExample) | ||
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| JP2017513894A5 (enExample) | ||
| JP2019513778A5 (enExample) | ||
| JP2018524338A5 (enExample) | ||
| JP2010513444A5 (enExample) | ||
| JP2014523400A5 (enExample) | ||
| JP2007510689A5 (enExample) | ||
| JP2010539188A5 (enExample) | ||
| JP2010533158A5 (enExample) | ||
| JP2007523905A5 (enExample) | ||
| RU2012112151A (ru) | Соединения как модуляторы тирозинкиназы | |
| JP2012520238A5 (enExample) | ||
| RU2015122698A (ru) | Производное пиридина | |
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| JP2007519695A5 (enExample) | ||
| RU2011134868A (ru) | N-замещенные насыщенные гетероциклические сульфоновые соединения с активностью агонистов рецептора св2 |